Biotechnology

In a new age of personalised cancer therapy, is patent law in Europe still fit for purpose?

In the last week it has been announced that the NHS has struck a deal with Novartis to offer their ground-breaking new CAR-T therapy, Kymriah®, to paediatric patients with B cell acute lymphoblastic leukaemia. This is a significant development and means that some patients will now have access to this...

Read more

Asking the right questions to optimise life sciences IP

This article was originally published on Biotech and Money. Supporting commercial goals by asking ‘why?’ As there is no one-size-fits-all approach to developing an effective IP strategy, GJE ensures it has a thorough understanding of its clients’ objectives and developments within their businesses so that it is able to offer the...

Read more

The growth finance landscape in biotech

Ian Jones took the helm of a lively panel debate at the Biotech and Money/Medtech and Money World Congress 2018 on the continued influence of venture capital on the sector and their appetite for growth and follow-on investment. Speaking on the panel were the following venture capital and corporate venturing...

Read more

Biotech vs Medtech: Differences in Mapping an IP Portfolio

This article was originally published on Biotech and Money as a two-part series. Read part one here. IP portfolio management is often overlooked, but is extremely important if the goal is to protect products or services in the most cost-efficient way possible. However, the process of mapping an IP portfolio to...

Read more

Biotech vs Medtech: Divergence in Intellectual Property Strategy

The landscape of innovation and investment in the healthcare sector has changed dramatically with the digital revolution and the rise of medtech – the physical devices used in healthcare – ranging from drug delivery devices to diagnostic kits and software for the interpretation of health and wellbeing data. Investors in...

Read more